Cell Culture Specialists are key players in biotechnology and pharmaceutical industries, responsible for growing and maintaining cell cultures in controlled laboratory environments. Their expertise lies in optimizing conditions for cells to thrive, including managing temperature, pH, and nutrient levels. These professionals cultivate cells to produce biological products such as vaccines, therapeutic proteins, and monoclonal antibodies. Their work is fundamental to the development of new treatments and is integral to drug testing, vaccine development, and disease research. Through careful manipulation of cell lines and cultivation techniques, they ensure the production of high-quality and consistent biological products.
Cell culture specialists are involved in scaling up processes for large-scale production. They address challenges related to cell growth rates, contamination control, and maximizing yield, ensuring that cells continue to function effectively in industrial settings. Their work also intersects with quality control teams to ensure all products meet rigorous regulatory standards. Cell culture technology is indispensable in advancing medical treatments, including therapies for cancer, diabetes, and autoimmune diseases. Cell culture specialists are crucial to the success of medical innovations, as they enable the production of life-saving biologic therapies. Their continued expertise is essential for improving the efficiency and effectiveness of biopharmaceutical production. As demand for biologic therapies grows, their role becomes even more vital in meeting global healthcare needs.
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France
Title : THE HPV vaccination program in Colombia. From a beautiful dream to a nightmare, but hopefully with a bright dawn.
Carlos Castro, Colombian League against cancer, Colombia